활성 루푸스 신장염(Active lupus nephritis)을 표준 치료에다 벨리무맙을 포함해 치료하는 치료효과가 월동하는 염증입니다. In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone.

활성 루푸스 신장염(Active lupus nephritis)을 표준 치료에다 belimumab을 첨가해 치료 하면 치료효과가 월씬 좋다고 한다.

In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone. 소스:  Rheumatology Update from NEJM.org 10/2020